CO 1024
Alternative Names: CO-1024Latest Information Update: 07 May 2024
At a glance
- Originator Corellia AI
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 25 Apr 2024 CO 1024 is available for licensing as of 25 Apr 2024. https://corellia.ai/partnering (Corellia AI pipeline, Aril 2024)
- 25 Apr 2024 Preclinical trials in Solid tumours in USA (Parenteral) prior to April 2024 (Corellia AI pipeline, Aril 2024)